Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

3.62
+0.12003.43%
Post-market: 3.53-0.0900-2.49%19:45 EDT
Volume:1.16M
Turnover:4.17M
Market Cap:246.65M
PE:-3.54
High:3.69
Open:3.50
Low:3.41
Close:3.50
Loading ...

Corvus Pharmaceuticals Announces Presentation of Additional Data From the Phase 1/1B Clinical Trial of Soquelitinib for Patients With T Cell Lymphoma

THOMSON REUTERS
·
20 Mar

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

GlobeNewswire
·
20 Mar

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire
·
20 Mar

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

GlobeNewswire
·
18 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Corvus Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Buy Recommendation for Corvus Pharmaceuticals Driven by Soquelitinib’s Promising Trial Results and Strong Financial Position

TIPRANKS
·
14 Jan

BRIEF-Corvus Pharmaceuticals Announces Data From Cohort 2 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

Reuters
·
13 Jan

Corvus announces data from cohort 2 of Phase 1 trial of Soquelitinib

TIPRANKS
·
13 Jan

Corvus Pharmaceuticals Inc - Data Show Favorable Safety and Efficacy Profile

THOMSON REUTERS
·
13 Jan

Corvus Pharmaceuticals Announces Data From Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

THOMSON REUTERS
·
13 Jan

Corvus Pharmaceuticals Inc - Cohort 2 Fully Enrolled, Full Results Expected in Q2 2025

THOMSON REUTERS
·
13 Jan

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

GlobeNewswire
·
13 Jan

We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn

Simply Wall St.
·
07 Jan

Analysts Offer Insights on Healthcare Companies: Bioventus (BVS), Corvus Pharmaceuticals (CRVS) and Lifecore Biomedical (LFCR)

TIPRANKS
·
02 Jan

BUZZ-H.C. Wainwright starts coverage of Corvus Pharmaceuticals with 'buy' rating

Reuters
·
02 Jan

Corvus Pharmaceuticals Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
02 Jan

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS) and Veru (VERU)

TIPRANKS
·
02 Jan

Corvus Pharmaceuticals, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $11

THOMSON REUTERS
·
02 Jan

Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS), Healthcare Services (HCSG) and Verastem (VSTM)

TIPRANKS
·
21 Dec 2024